Clinical trials: Hepatitis E
Chronic Hepatitis B Virus Infection
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT05970289
- Testing
- PEG-IFNα, BRII-835
- Where
- 28 sites in Australia, China and 3 more
- Volunteers
- 86 people
- Sponsor
- Brii Biosciences Limited
Hepatitis B
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia
The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia. Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will…
- Trial name
- NCT06586983
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Ethiopia
- Volunteers
- 4,500 people
- Sponsor
- Oslo University Hospital
Hepatitis C, Chronic, Pregnancy; Infection
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
- Trial name
- STORC (NCT05140941)
- Testing
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Catherine Anne Chappell
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07876856
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Cirrhosis
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Background: Hepatitis C infection (HCV) is a leading cause of liver disease. Normal bacteria from the intestines may spread to the liver and blood during liver disease. This is called bacterial translocation (BT).
- Trial name
- NCT02400216
- Testing
- dual cholate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b, Women
Efficacy and Adverse Effects of Nucleoside Analogues (TDF/LDT) in Preventing Mother-to-child Transmission of HBV
Mother-to-Child-Transmission (MTCT) of HBV is the most important route in high endemic countries. Although active-passive immune prophylaxis is generally administrated to infants delivered by HBsAg positive women, there are a lot…
- Trial name
- NCT03181607
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Xingfei Pan
Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive…
- Trial name
- NCT05294744
- Testing
- N-acetylcysteine
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Bioaraba Health Research Institute
Hepatitis B Virus Infection; Pregnant Women
TAF vs TDF During the Pregancy
The goal of this clinical trial is to learn the efficacy and safety of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate(TDF) in early and middle pregnancy antiviral therapy for chronic hepatitis B pregnant women.
- Trial name
- TAF；TDF；RCT (NCT07542951)
- Testing
- TAF
- Where
- China
- Volunteers
- 210 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Autoimmune Hepatitis, AIH
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and…
- Trial name
- MERCURY (NCT07598825)
- Testing
- Inebilizumab, Standard of Care
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Amgen
Inflammatory Bowel Diseases
Efficacy of Accelerated Versus Standard Regiment of Hepatitis B Virus Vaccine Among Inflammatory Bowel Disease Patients
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that includes ulcerative colitis (UC) and Crohn's disease (CD) .
- Trial name
- NCT05967650
- Testing
- standard hepatitis B vaccine, accelerated HBV Vaccine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Chronic Hepatitis D
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
The goal of this clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016.
- Trial name
- NCT06649266
- Testing
- RBD1016
- Where
- 2 sites in Sweden
- Volunteers
- 14 people
- Sponsor
- Ribocure Pharmaceuticals AB
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
Hepatitis B, HIV
Integrating Hepatitis B Elimination Into the HIV Program in Zambia
The goal of this study is to develop an integrated HBV-HIV service care model in Zambia by working with people living with HBV, healthcare workers, policy makers and other key stakeholders to co-design an intervention.
- Conditions
- Hepatitis B, HIV, Implementation Science
- Trial name
- INTEGRATE B (NCT07875218)
- Testing
- Integrated HBV/HIV Service Delivery Model
- Where
- Zambia
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Hepatitis B
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
This Phase 1/2a multiple part study is a first time-in-human (FTIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2) of GSK3965193 in healthy…
- Trial name
- NCT05330455
- Testing
- GSK3965193, Bepirovirsen
- Where
- 14 sites in Canada, France and 4 more
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Virus - Chronic Active
Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women
Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery.
- Trial name
- TOPCHIB (NCT05403047)
- Testing
- Fumarate, Tenofovir Disoproxil
- Where
- Cameroon
- Volunteers
- 150 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis b Virus, Hepatitis B
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB…
- Trial name
- NCT05856890
- Testing
- HepB mAb19, Sterile Saline
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Rockefeller University
Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
Persuasive Health Communication Intervention for HIV/HCV
A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing.
- Trial name
- NCT05968573
- Testing
- Video Format with Captions, Video Format without Captions, Health Educator
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Chronic Hepatitis B Infection
A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults
This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.
- Trial name
- NCT07059403
- Testing
- SN2001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chimivac INC
Hepatitis B, Chronic
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-201 (NCT07370207)
- Testing
- AHB-137
- Where
- 10 sites in Australia, China and 5 more
- Volunteers
- 84 people
- Sponsor
- AusperBio Therapeutics Inc.